Literature DB >> 26879277

Ozanimod: a better or just another S1P receptor modulator?

Per Soelberg Sørensen1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26879277     DOI： 10.1016/S1474-4422(16)00041-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  3 in total

1.  Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.

Authors:  Jonathan Q Tran; Jeffrey P Hartung; Robert J Peach; Marcus F Boehm; Hugh Rosen; Heather Smith; Jennifer L Brooks; Gregg A Timony; Allan D Olson; Sheila Gujrathi; Paul A Frohna
Journal:  J Clin Pharmacol       Date:  2017-04-11       Impact factor: 3.126

2.  Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.

Authors:  Jonathan Q Tran; Jeffrey P Hartung; Cindy-Ann Tompkins; Paul A Frohna
Journal:  Clin Pharmacol Drug Dev       Date:  2017-11-10

Review 3.  Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown.

Authors:  Heather E Moss
Journal:  Eye Brain       Date:  2017-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.